Get the Weekly Intelligence Brief — top committee picks every Sunday.
XRAY · NASDAQ · STOCK

Dentsply Sirona (XRAY) Stock Analysis

Healthcare Updated September 06, 2026
$11.38
52W $9.41 – $14.76
54/100
$2.28B
-4.2
0.85
AI Committee Verdict
Watch
54/100
Conviction: Contested · 33% agreement · 6 analysts
+14.3%
-4.6%
3.11:1
Contested

Is XRAY Bullish or Bearish?

Mixed. Innellis AI committee rates Dentsply Sirona (XRAY) Watch with a composite score of 54/100 , based on 6 analysts with 33% agreement. Last updated September 06, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +6.22 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -13.78 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — high leverage (debt-to-equity 1.74) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Dividend yield of 5.5% pays you to wait — Value
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • News sentiment is positive (+0.38 across 8 articles, 14d) — News
Bear Case
  • ROE of only -39.8% -- cheap may mean cheap for a reason — Value
  • Debt-to-equity of 1.74 adds balance-sheet risk to the value case — Value
  • Revenue declining -0.8% YoY -- this is not a growth story right now — Growth
  • Price structure making lower highs and lower lows — Technical
  • Price structure (HH_HL) contradicts the downtrend -- mixed signals — Technical
  • High leverage (debt-to-equity 1.74) amplifies downside in a stress scenario — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of September 06, 2026
Overall Committee Score
54/100
Agreement
33%
Analysts
6
Conviction
Contested
Sector Rank
Top 89%
of 192 Healthcare peers
Value Analyst bearish
40 / 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
+ Dividend yield of 5.5% pays you to wait
− ROE of only -39.8% -- cheap may mean cheap for a reason
Growth Analyst neutral
50 / 100 · Moderate confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− Revenue declining -0.8% YoY -- this is not a growth story right now
Technical Analyst neutral
53 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− Price structure making lower highs and lower lows
Risk Analyst bearish
30 / 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 1.74) amplifies downside in a stress scenario
Macro Analyst bullish
80 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst bullish
70 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.38 across 8 articles, 14d)
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2704.43)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 53.8 to 53.8.

Comparing 2026-09-05 to 2026-09-06 (1 day apart).

Technical Analysis

RSI (14)
53.7
Neutral
MACD Histogram
0.066
Bullish Momentum
Trend Direction
Downtrend
Weekly: Downtrend
Market Structure
Hh Hl
Support
$10.86
Resistance
$13.01
Bollinger %B
0.67
Inside Bands
Price vs Moving Averages
EMA 9
$11.22 Above
EMA 21
$11.45 Below
EMA 50
$11.69 Below
EMA 200
$12.19 Below

Fundamental Analysis

Valuation
99
Growth
72
Profitability
18
Financial Health
54
Cash Flow
70
Valuation
P/E Ratio -4.2×
P/B Ratio 1.68×
PEG Ratio -0.08
Dividend Yield 2.81%
52W High $14.76
52W Low $9.41
Quality & Growth
ROE -4462.7%
ROA -1101.5%
Gross Margin 4952.0%
Operating Margin 1169.4%
Revenue Growth YoY
Debt / Equity 1.71
AI Fundamental Assessment
P/E ratio of -4.2 (inexpensive relative to a 15-40x range); Price-to-book of 1.7x; PEG ratio of -0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -44.6%; Return on assets of -11.0%; Net margin of -15.0%; Gross margin of 49.5%; Current ratio of 1.63 (healthy short-term liquidity); Debt-to-equity of 1.71; Free cash flow per share is positive (0.72); Most recent quarter beat estimates by 46.1%; EPS growth accelerating (+0.0% -> +92.6% QoQ); Average YoY EPS growth of 0.0%; Analyst estimates rising over recent quarters
Get the Full XRAY Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime